Previous Article | Next Article 
Journal of Clinical Microbiology, November 1998, p. 3160-3163, Vol. 36, No. 11
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Prevalence of Human Calicivirus Infections in Kenya
as Determined by Enzyme Immunoassays for Three Genogroups of
the Virus
Shuji
Nakata,1,*
Shinjiro
Honma,1
Kazuko
Numata,1
Keiko
Kogawa,1
Susumu
Ukae,1
Noriaki
Adachi,1
Xi
Jiang,2
Mary K.
Estes,3
Zippora
Gatheru,4
Peter M.
Tukei,4 and
Shunzo
Chiba1
Department of Pediatrics, Sapporo Medical
University School of Medicine, Sapporo, Japan1;
Center for Pediatric Research, Children's Hospital of the
King's Daughters, Eastern Virginia Medical School, Norfolk,
Virginia2;
Division of Molecular
Virology, Baylor College of Medicine, Houston,
Texas3; and
Virus Research Center,
Kenya Medical Research Institute, Nairobi,
Kenya4
Received 3 June 1998/Returned for modification 20 July
1998/Accepted 11 August 1998
 |
ABSTRACT |
An epidemiological survey on human calicivirus (HuCV) infections
and associated gastroenteritis in infants was conducted to clarify the
prevalence of HuCV infections in infants and adults in Kenya. Enzyme
immunoassays (EIAs) for three genogroups of HuCVs, Norwalk virus (NV),
Mexico virus (MXV), and Sapporo virus (SV), were used to detect antigen
or antibody. We tested 1,431 stool samples obtained from children
younger than 6 years old with acute gastroenteritis who visited
outpatient clinics in three districts in Kenya from August 1991 to July
1994. Thirty-two (2.2%) of these stool samples were positive for SV
antigen. Only one (0.1%) of 1,186 samples was positive for NV antigen
and none of 246 samples was positive for MXV antigen. One hundred
ninety-three serum samples were tested for antibodies to NV and MXV,
and 64 of them were examined for antibody to SV. The pattern of the
age-related prevalence of serum antibody to NV was different from that
of antibodies to MXV and SV. The acquisition of serum antibodies to
HuCVs in the three genogroups appeared in early childhood, at about 1 to 2 years of age. The prevalence of serum antibody to NV was low (about 60%) throughout adulthood compared with a high prevalence of
antibody (~80 to 90%) to MXV and SV. These data indicate that infections with viruses in the three genogroups of HuCVs are common in
Kenya, and immunological responses to NV may be different from those to
MXV and SV. The EIAs for the detection of NV and MXV antigens appear to
be quite specific for prototype NV and MXV strains, respectively, so
that they can detect only a few strains of HuCVs related to them.
Alternatively, NV and MXV caused less severe infections that did not
bring children to the outpatient clinics for gastroenteritis in Kenya.
 |
INTRODUCTION |
Research work on viral
gastroenteritis in Kenya has focused on only group A rotaviruses so far
(4, 19, 23, 30), mainly because of the clinical importance
of group A rotaviruses. Another reason is that a practical method like
enzyme immunoassay (EIA) for the detection of other gastroenteritis
viruses, especially for human caliciviruses (HuCVs), is not available
in that country. HuCVs have been divided into at least three genogroups
(genogroup I, represented by Norwalk virus [NV]; genogroup II,
represented by Snow Mountain virus; and genogroup III, represented by
Sapporo virus [SV] [2, 8, 25]) on the basis of
genome analysis of the RNA-dependent RNA polymerase region and capsid
protein region and also differences in antigenicity. Because of these antigenic differences in HuCVs, at least three kinds of EIA systems are
needed to detect these HuCVs. Such EIAs have been limited to only a few
research institutes in the world because of a limited supply of the
reagents.
The recent success of NV and Mexico virus (MXV; genogroup II HuCV) gene
cloning and the production of the recombinant NV (rNV) and recombinant
MXV (rMXV) capsid proteins by the baculovirus expression system
(11, 14) has resulted in the availability of an unlimited
amount of rNV and rMXV antigen and high-titer hyperimmune sera to rNV
and rMXV to enable large-scale epidemiological studies. The EIA for SV
is available at the Department of Pediatrics, Sapporo Medical
University, Sapporo, Japan (22). Previous
seroepidemiological studies by these EIAs indicate that infection with
NV, MXV, or SV is very common in the world (9, 10, 18, 20, 21, 24,
26-28).
Because a systematic survey of the HuCV infections and associated
gastroenteritis in infants has not been conducted in Kenya, we
conducted an epidemiological study to clarify the prevalence of HuCV
infections in infants and adults in Kenya. Diarrheal stool samples
obtained from infants who were mainly outpatients in two districts and
in Nairobi, Kenya, were examined by the EIAs for viruses in the three
genogroups of HuCVs to clarify the importance of HuCVs in causing
infantile gastroenteritis in an outpatient setting. The age-related
prevalence of serum antibody to three HuCVs was also examined by
blocking EIAs (10, 22, 24).
 |
MATERIALS AND METHODS |
Clinical specimens.
One thousand four hundred thirty-one
stool samples were collected from children younger than 6 years old
with acute gastroenteritis who were visiting outpatient clinics in
Nanyuki, Kitui, and Nairobi, Kenya, from August 1991 to July 1994. Fifty-three percent of the stool samples were obtained from infants
younger than 11 months old, 34% were from children 12 to 24 months
old, 7% were from children 25 to 36 months old, and 6% were from
children 37 to 72 months old. These samples had been examined by
conventional EIA for group A rotavirus and by EIA with monoclonal
antibodies to either type 40 or type 41 enteric adenoviruses
(23). These samples were also tested by the antigen EIA for
SV (genogroup III human calicivirus) (22). One thousand one
hundred eighty-six stool specimens were examined by the antigen EIA for
NV (genogroup I human calicivirus) (24), and 246 stool
specimens were examined by the EIA for MXV (genogroup II human
calicivirus) (10, 13). Stool samples were prepared as a 10%
(wt/vol) suspension in 10 mM phosphate-buffered saline (PBS; pH 7.4)
and clarified by centrifugation at 7,000 × g for 20 min. The aqueous phase was stored at 4°C until it was tested.
Serum specimens.
Eighty serum specimens were collected from
adult patients (ages, 20 to more than 50 years) with liver diseases in
Mombasa, Machakos, and Nairobi, Kenya, from 1991 to 1995. One hundred
thirteen serum specimens were obtained from children (ages, 0 months to 19 years) without gastroenteritis who were chronic hepatitis B virus
carrier cases in Maragua in Kenya from 1986 to 1989 (32). For testing, these sera were divided into 10 groups according to the
ages of the donors (0 to 3, 4 to 11, and 12 to 23 months and 2 to 5, 6 to 11, 12 to 19, 20 to 29, 30 to 39, 40 to 49, and older than 50 years), and 18, 18, 19, 19, 19, 20, 20, 20, 20, and 20 samples from
individuals in each age group, respectively, were tested for antibodies
to NV and MXV. For the detection of antibody to SV, 5, 10, 8, 13, 11, and 11 samples from individuals in each of the age groups consisting of
individuals younger than 19 years, respectively, and 6 serum samples
from adults ages 20 to 29 years were tested. All serum specimens were
stored at
20°C until they were used and were tested without
knowledge of the age of the subjects.
Baculovirus-expressed NV or MXV capsid antigen.
NV and MXV
capsid antigens (rNV and rMXV, respectively), which were produced by
the baculovirus expression system, were obtained as described
previously (11, 14). rNV and rMXV were diluted to a
concentration of 1 µg/ml and were used for the following experiments.
EIA for detection of three genogroups of caliciviruses.
The
EIAs for SV antigen and for NV antigen in stools were done as described
previously (22, 24). The EIA for MXV antigen was performed
in the same way as described above for the EIAs for SV and NV antigens,
but a modified EIA which was different from the original EIA for MXV
antigen described previously (13) was used. The sensitivity
and specificity of the EIA for MXV antigen have been described
elsewhere (10). Briefly, PBS containing 10% fetal calf
serum, 1% bovine serum albumin (BSA), and 0.05% Tween 20 was used as
the dilution buffer for stool samples, blocking serum, and detector
antibody. The peroxidase-conjugated goat antibody to rabbit
immunoglobulin G was diluted in PBS containing 5% normal guinea pig
serum, 1% BSA, and 0.05% Tween 20. Duplicate wells of the 96-well
polyvinyl chloride flat-bottom microtiter plates (Dynatech
Laboratories, Inc., Alexandria, Va.) were each coated with 100 µl of
a 1:10,000 dilution of either hyperimmune guinea pig serum to MXV or
preimmune guinea pig serum diluted in 10 mM PBS (pH 7.4), and the
plates were incubated at 4°C overnight. The plates were then washed
five times with PBS containing 0.05% Tween 20 (PBS-T) and were blocked
with 1% BSA in PBS for 60 min at 37°C. The residual blocking fluid
was then removed, 50 µl of the dilution buffer was added to all
wells, and then 25 µl of each test sample (10% stool suspension) was
added. The plates were incubated at 4°C overnight. After five
washings in PBS-T, 50 µl of a 1:5,000 dilution of rabbit serum
hyperimmune to MXV was added, and the plates were incubated for 90 min
at 37°C. After five washings in PBS-T, 50 µl of a 1:10,000 dilution
of peroxidase-conjugated goat antibody to rabbit immunoglobulin G
(Seikagaku Corporation, Tokyo, Japan) was added. The plates were
incubated for 90 min at 37°C and washed five times in PBS-T. A
100-µl portion of o-phenylenediamine dihydrochloride (0.4 mg/ml; Wako Pure Chemical Industries, Ltd., Osaka, Japan) in 0.15 M
citric acid buffer (pH 4.0) containing 0.4 µl of 30%
H2O2 per ml was added to each well, and the
plates were incubated for 30 min at room temperature. The reaction was stopped with 100 µl of 1 M H2SO4, and the
A492 was measured with an EIA reader (Easy
Reader EAR400; SLT-Labinstruments).
For each sample, the results were expressed as the ratio of the
A492 for wells coated with hyperimmune serum
(positive) to the A492 for wells coated with
preimmune serum (negative) (P/N ratio). The cutoff value of this system
was obtained by testing 20 stool suspensions from patients with group A
rotavirus gastroenteritis. The mean P/N ratio of these samples plus 3 standard deviations was 1.7. A P/N ratio of >1.7 and an
A492 of >0.075 were considered to indicate a
positive reaction. All tests were performed in duplicate, and the
results were averaged. The optimal dilutions of reagents were
determined by checkerboard titrations with rMXV capsid protein and 10%
stool suspensions containing group A rotavirus. Positive controls
consisting of rNV, rMXV, and SV antigens were run in each plate.
Blocking EIA for detection of antibodies for three genogroups of
caliciviruses.
Antibodies to NV, MXV, and SV were measured by a
blocking EIA (10, 22, 24). This format was used in this
laboratory (Department of Pediatrics, Sapporo Medical University) to
measure antibody to a variety of enteric viruses because of the
advantages described previously (24). The sensitivity and
specificity of this EIA are described elsewhere (10).
Statistical analysis.
Student's t test or
chi-square analysis was used where appropriate.
 |
RESULTS |
Prevalence of gastroenteritis viruses in Kenya.
The prevalence
of gastroenteritis viruses in stool samples obtained from children
younger than 6 years old who had acute gastroenteritis from August 1991 to July 1994 was as follows: group A rotavirus was the main virus
detected every year and had a prevalence of 22.2% (range, 20.9 to
23.7%), followed by HuCVs at 2.2% (range, 0.7 to 4.9%) and enteric
adenoviruses (type 40 and type 41) at 1.4% (range, 1.2 to 1.6%) (data
not shown).
Detection of three genogroups of caliciviruses in diarrheal stool
samples.
One thousand one hundred eighty-six stool specimens were
tested for NV antigen by the EIA. Only one (0.1%) of them was positive for NV antigen. The patient was a 6-month-old female who had a clinically mild case of diarrhea of 2 days' duration and 1 day of
vomiting. Although this positive sample was tested by reverse transcription-PCR with the 35-36 primer set for the RNA polymerase region (12), no PCR product was obtained, probably because
of the presence of inhibitors in the stool sample. The presence of inhibitors was confirmed by inhibition of amplification of an internal
standard to this sample (data not shown).
Thirty-two (2.2%) of 1,431 stool samples were positive for SV by the
EIA for the SV antigen. The age distribution of the patients infected
with SV ranged from 5 months to 6 years and 11 months (mean, 17.7 months), and the sex ratio (number of males/number of females) was
1.75. The seasonal shedding of SV from August 1991 to July 1994 is
shown in Fig. 1. In a tropical climate
like Kenya, there are two seasons, dry and wet periods. In Kenya, the wet period usually lasts from April to July and from November to
December and the rest of the year is the dry period. SV was constantly
detected every year without regard to the climate in Kenya.
Complete clinical information was available for 1,286 of 1,431 patients. Although the mean duration of diarrhea due to SV (6.22 days;
22 samples) was longer than that due to group A rotaviruses (3.98 days;
284 samples), enteric adenoviruses (4.13 days; 20 samples), and no
virus (4.55 days; 960 samples), there was no statistically significant
difference among them (t test). However, the prevalence of
persistent diarrhea which continued for more than 14 days was
significantly higher in patients with diarrhea due to SV (5 of 22) than
in patients with diarrhea due to group A rotaviruses (7 of 284) and no
virus (48 of 960) (chi-square test).
Two hundred forty-six stool specimens were tested for the MXV antigen
by EIA. None of them was positive for the MXV antigen.
Prevalence of antibodies to three genogroups of caliciviruses.
The age-related prevalence of serum antibodies to NV, MXV, and SV in
Kenya is shown in Fig. 2. Six (33.3%) or
seven (38.9%) of 18 infants below the age of 3 months had antibody to
NV or MXV, respectively. The prevalence of serum antibody decreased thereafter and reached a minimum in the group consisting of 4- to
11-month-old children (22.2 and 11.1%, respectively). The rate of
positivity for antibody to MXV steeply increased among
preschool-age children, reached a maximum of more than 90% in the
group consisting of 12- to 19-year-olds, and was maintained thereafter.
On the other hand, the prevalence of serum antibody to NV increased to 58% in infants ages 12 to 23 months and was maintained thereafter at
between 50 and 70%. The prevalence of serum antibodies to NV and MXV
was statistically different (P < 0.01 and
P < 0.05, respectively [chi-square test]) in the
groups consisting of individuals older than 12 years of age (Fig. 2).
Although the sample number was smaller for SV-infected patients than
those for patients infected with the other two viruses, the pattern of
acquisition of serum antibody was similar to those for NV and MXV,
except that no clear decrease in antibody prevalence was seen in the
group consisting of individuals 4 to 11 months of age. The rate of
positivity for antibody to SV was maintained at between 70 and 90%
from infants to adults.

View larger version (43K):
[in this window]
[in a new window]
|
FIG. 2.
Age-related prevalence of antibody to NV ( ), MXV
( ), and SV ( ) in Kenya. *, P < 0.01; #,
P < 0.05 (chi-square test). M, month; Y, year.
|
|
 |
DISCUSSION |
This is the first systematic study to investigate the role of
three genogroups of HuCVs in causing gastroenteritis in an outpatient setting. SV-related strains were detected every year in 1 to 4% of
diarrheal stool samples from infants younger than 6 years old, whereas
NV and MXV were rarely detected or were not detected. However, the
seroepidemiological study in Kenya suggested that acquisition of
antibodies to three genogroups of HuCVs starts in early childhood and
that infections with these three viruses are common in Kenya.
Several possibilities may explain the low rate of detection or lack of
detection of NV and MXV compared to the high prevalence of antibodies
to these viruses. First, the EIA for rNV or rMXV antigen detection is
quite specific for prototype NV or MXV strains and may detect only a
few strains of genogroup I or II HuCVs which are antigenically and
genetically close to those prototype viruses (5, 24).
Actually, the EIA for rMXV, subgenogroup 2 of HuCV genogroup II,
detects only a subset of subgenogroup 1 of HuCV genogroup II-positive
samples (13). More broadly reactive EIAs are required to
overcome the possible explanation for the low rate of detection of NV
and MXV antigen in stool samples described above. Second, the positive
reactions for NV or MXV antibody by the EIA may reflect separate
infections with HuCVs of the same genogroup. Serological responses can
detect the antigenic relatedness among viruses of the same genogroup
more broadly than the antigen detection method (16). Third,
NV and MXV gastroenteritis might be milder than SV infections and may
not require visits to outpatient clinics. Finally, these viruses may
cause diseases other than acute gastroenteritis. Low rates of detection
of NV and MXV in infantile gastroenteritis were also demonstrated in
Japan (10, 24) and the United Kingdom (1, 26), so
that practical methods for the detection of the antigen more broadly
and the examination of large numbers of samples are needed.
SV seemed to be an important gastroenteritis virus along with group A
rotavirus as a cause of infantile viral gastroenteritis in Kenya. This
virus was constantly detected in Kenya every year without seasonality,
which was similar to the findings for developed countries like Japan
(17). Interestingly, the prevalence of persistent diarrhea
continuing for 14 days or longer was significantly higher in patients
infected with calicivirus than in patients infected with group A
rotavirus and patients who were virus negative. A combination of SV
infection with other factors in Kenya might play a role in this
phenomenon because similar findings were not found in Japan. Two
reports have suggested a relationship between enteric adenovirus
gastroenteritis and persistent diarrhea (7, 29), but another
report does not (31). Further investigation is required to
clarify the causes of persistent diarrhea, which increases the risk of
malnutrition and mortality among children in developing countries.
Generally, NV infection is more prevalent in developing countries than
in developed countries, and differences in hygienic conditions between
those countries may be one of the factors responsible for this
difference (15). However, a high prevalence of antibody to
NV was reported even in developed countries after the introduction of
sensitive immunoassays like radioimmunoassay and EIA (3, 6,
24), whereas a lower prevalence has been reported in the other
developed countries like the United Kingdom (26) and Norway (20). In contrast, even adults in developing countries, like Kenya in this study, show a low prevalence of antibody to NV. One
possible explanation may be that there is a difference in sensitivity
to NV infection among individuals of different races. Some individuals
remained resistant to NV infection even after virus challenge in
volunteer studies, whereas others sensitive to NV have been repeatedly
infected with NV following sequential challenge (16).
Further investigation of the sensitivities of black African and
Scandinavian individuals to NV is required to clarify these
possibilities. The other possibility is that a low population density
may result in a low rate of infection with NV (3, 26). The
sera from adults in Kenya used in this study were collected from adults
residing in rural areas.
Whereas EIAs for the detection of antigens of and antibodies to the
three genogroups of human caliciviruses are now available, the
development of more broadly reactive EIAs is necessary to clarify more
precisely the natural history and epidemiology of human calicivirus
infections throughout the world.
 |
ACKNOWLEDGMENTS |
This study was supported in part by grant 044543878 from the
Ministry of Education, Science, and Culture of Japan, by grants from
the U.S. Public Health Service (grants HD-13021 and AI 28855), by the
Jeffress Research Grant Foundation (grant J-303), and by U.S. Public
Health Service grant AI 38036.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Pediatrics, Sapporo Medical University School of Medicine, S.1 W.16, Chuo-ku, Sapporo, 060, Japan. Phone: 81-11-611-2111. Fax:
81-11-611-0352. E-mail: snakata{at}sapmed.ac.jp.
 |
REFERENCES |
| 1.
|
Cubitt, W. D., and X. Jiang.
1996.
Study on occurrence of human calicivirus (Mexico strain) as cause of sporadic cases and outbreaks of calicivirus-associated diarrhoea in the United Kingdom, 1983-1995.
J. Med. Virol.
48:273-277[Medline].
|
| 2.
|
Estes, M. K., and M. E. Hardy.
1995.
Norwalk virus and other enteric caliciviruses, p. 1009-1034.
In
M. J. Blaser, et al. (ed.), Infections of the gastrointestinal tract. Raven Press, New York, N.Y.
|
| 3.
|
Gary, G. W.,
J. E. Kaplan,
S. E. Stine, and L. J. Anderson.
1985.
Detection of Norwalk virus antibodies and antigen with a biotin-avidin immunoassay.
J. Clin. Microbiol.
22:274-278[Abstract/Free Full Text].
|
| 4.
|
Gatheru, Z.,
N. Kobayashi,
N. Adachi,
S. Chiba,
J. Muli,
P. Ogaja,
J. Nyangao,
E. Kiplagat, and P. M. Tukei.
1993.
Characterization of human rotavirus strains causing gastroenteritis in Kenya.
Epidemiol. Infect.
110:419-423[Medline].
|
| 5.
|
Graham, D. Y.,
X. Jiang,
T. Tanaka,
A. R. Opekun,
H. P. Madore, and M. K. Estes.
1994.
Norwalk virus infection of volunteers: new insights based on improved assays.
J. Infect. Dis.
170:34-43[Medline].
|
| 6.
|
Greenberg, H. B.,
R. G. Wyatt,
J. Valdesuso,
A. R. Kalica,
W. T. London,
R. M. Chanock, and A. Z. Kapikian.
1979.
Solid-phase microtiter radioimmunoassay for detection of the Norwalk strain of acute non-bacterial, epidemic gastroenteritis virus and its antibodies.
J. Med. Virol.
2:97-108.
|
| 7.
|
Grimwood, K.,
R. Carzino,
G. L. Barnes, and R. F. Bishop.
1995.
Patients with enteric adenovirus gastroenteritis admitted to an Australian pediatric teaching hospital from 1981 to 1992.
J. Clin. Microbiol.
33:131-136[Abstract].
|
| 8.
|
Hardy, M. E.,
S. F. Kramer,
J. J. Treanor, and M. K. Estes.
1997.
Human calicivirus genogroup II capsid sequence diversity revealed by analyses of the prototype Snow Mountain agent.
Arch. Virol.
142:1469-1479[Medline].
|
| 9.
|
Hinkula, J.,
J. M. Ball,
S. Lofgren,
M. K. Estes, and L. Svensson.
1995.
Antibody prevalence and immunoglobulin IgG subclass pattern to Norwalk virus in Sweden.
J. Med. Virol.
47:52-57[Medline].
|
| 10.
|
Honma, S.,
S. Nakata,
K. Kogawa,
K. Numata,
T. Yamashita,
M. Oseto,
X. Jiang, and S. Chiba.
1998.
Epidemiological study of genogroup II human calicivirus (Mexico virus) infections in Japan and Southeast Asia as determined by enzyme-linked immunosorbent assays.
J. Clin. Microbiol.
36:2481-2484[Abstract/Free Full Text].
|
| 11.
|
Jiang, X.,
M. Wang,
D. Y. Graham, and M. K. Estes.
1992.
Expression, self-assembly, and antigenicity of Norwalk virus capsid protein.
J. Virol.
66:6527-6532[Abstract/Free Full Text].
|
| 12.
|
Jiang, X.,
M. Wang,
D. Y. Graham, and M. K. Estes.
1992.
Detection of Norwalk virus in stool by polymerase chain reaction.
J. Clin. Microbiol.
30:2529-2534[Abstract/Free Full Text].
|
| 13.
|
Jiang, X.,
W. D. Cubitt,
J. Hu,
X. Dai,
J. Treanor,
D. O. Matson, and L. K. Pickering.
1995.
Development of an ELISA to detect MX virus, a human calicivirus in the Snow Mountain agent genogroup.
J. Gen. Virol.
76:2739-2747[Abstract/Free Full Text].
|
| 14.
|
Jiang, X.,
D. O. Matson,
G. M. Ruiz-Palacios,
J. Hu,
J. Treanor, and L. K. Pickering.
1995.
Expression, self-assembly, and antigenicity of a Snow Mountain agent-like calicivirus capsid protein.
J. Clin. Microbiol.
33:1452-1455[Abstract].
|
| 15.
|
Kapikian, A. Z., and R. M. Chanock.
1996.
Rotaviruses, p. 1657-1708.
In
B. N. Fields, et al. (ed.), Virology. Raven Press, New York, N.Y.
|
| 16.
|
Kapikian, A. Z.,
M. K. Estes, and R. M. Chanock.
1996.
Norwalk group of viruses, p. 783-810.
In
B. N. Fields, et al. (ed.), Virology. Raven Press, New York, N.Y.
|
| 17.
|
Kogawa, K.,
S. Nakata,
S. Ukae,
N. Adachi,
K. Numata,
D. O. Matson,
M. K. Estes, and S. Chiba.
1996.
Dot blot hybridization with a cDNA probe derived from the human calicivirus Sapporo 1982 strain.
Arch. Virol.
141:1949-1959[Medline].
|
| 18.
|
Lew, J. F.,
J. Valdesuso,
T. Vesikari,
A. Z. Kapikian,
X. Jiang,
M. K. Estes, and K. Y. Green.
1994.
Detection of Norwalk virus or Norwalk-like virus infections in Finnish infants and young children.
J. Infect. Dis.
169:1364-1367[Medline].
|
| 19.
|
Mutanda, L. N.
1980.
Epidemiology of acute gastroenteritis in early childhood in Kenya: aetiological agents.
Trop. Geogr. Med. Hyg.
46:272-277.
|
| 20.
|
Myrmel, M.,
E. Rimstad,
M. K. Estes,
E. Skjerve, and Y. Wasteson.
1996.
Prevalence of serum antibodies to Norwalk virus among Norwegian military recruits.
Int. J. Food Microbiol.
29:233-240[Medline].
|
| 21.
|
Nakata, S.,
S. Chiba,
H. Terashima, and T. Nakao.
1985.
Prevalence of antibody to human calicivirus in Japan and Southeast Asia determined by radioimmunoassay.
J. Clin. Microbiol.
22:519-521[Abstract/Free Full Text].
|
| 22.
|
Nakata, S.,
M. K. Estes, and S. Chiba.
1988.
Detection of human calicivirus antigen and antibody by enzyme-linked immunosorbent assays.
J. Clin. Microbiol.
26:2001-2005[Abstract/Free Full Text].
|
| 23.
| Nakata, S., Z. Gatheru, S. Ukae, N. Adachi, N. Kobayashi, J. Muli, P. Ogaja, J. Nyangao, E. Kiplagat, P. M. Tukei, and S. Chiba. Epidemiological study of the G serotype
distribution of group A rotaviruses in Kenya from 1991 to 1994. Submitted for publication.
|
| 24.
|
Numata, K.,
S. Nakata,
X. Jiang,
M. K. Estes, and S. Chiba.
1994.
Epidemiological study of Norwalk virus infections in Japan and Southeast Asia by enzyme-linked immunosorbent assays with Norwalk virus capsid protein produced by the baculovirus expression system.
J. Clin. Microbiol.
32:121-126[Abstract/Free Full Text].
|
| 25.
|
Numata, K.,
M. E. Hardy,
S. Nakata,
S. Chiba, and M. K. Estes.
1997.
Molecular characterization of morphologically typical human calicivirus Sapporo.
Arch. Virol.
142:1537-1552[Medline].
|
| 26.
|
Parker, S. P.,
W. D. Cubitt,
X. Jiang, and M. K. Estes.
1994.
Seroprevalence studies using a recombinant Norwalk protein enzyme immunoassay.
J. Med. Virol.
42:146-150[Medline].
|
| 27.
|
Parker, S. P.,
W. D. Cubitt, and X. Jiang.
1995.
Enzyme immunoassay using baculovirus-expressed human calicivirus (Mexico) for the measurement of IgG responses and determining its seroprevalence in London, UK.
J. Med. Virol.
46:194-200[Medline].
|
| 28.
|
Taylor, M. B.,
S. Parker,
W. O. Grabow, and W. D. Cubitt.
1996.
An epidemiological investigation of Norwalk virus infection in South Africa.
Epidemiol. Infect.
116:203-206[Medline].
|
| 29.
|
Uhnoo, I.,
G. Wadell,
L. Svensson, and M. Johansson.
1984.
Importance of enteric adenoviruses 40 and 41 in acute gastroenteritis in infants and young children.
J. Clin. Microbiol.
20:365-372[Abstract/Free Full Text].
|
| 30.
|
Urasawa, T.,
S. Urasawa,
Y. Chiba,
K. Taniguchi,
N. Kobayashi,
L. N. Mutanda, and P. M. Tukei.
1987.
Antigenic characterization of rotaviruses isolated in Kenya from 1982 to 1983.
J. Clin. Microbiol.
25:1891-1896[Abstract/Free Full Text].
|
| 31.
|
Van, R.,
C. C. Wun,
M. L. O'Ryan,
D. O. Matson,
L. Jackson, and L. K. Pickering.
1992.
Outbreaks of human enteric adenovirus types 40 and 41 in Houston day care centers.
J. Pediatr.
120:516-521[Medline].
|
| 32.
|
Yamanaka, T.,
N. Takayanagi,
T. Nakao,
M. Kobayashi, and K. Baba.
1991.
Seroepidemiological study of hepatitis B (HBV) infection in the rural community of Kenya changing pattern of transmission mode of HBV in Kenya.
Kansenshogakuzasshi
65:26-34. (In Japanese.)
|
Journal of Clinical Microbiology, November 1998, p. 3160-3163, Vol. 36, No. 11
0095-1137/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Ozawa, K., Oka, T., Takeda, N., Hansman, G. S.
(2007). Norovirus Infections in Symptomatic and Asymptomatic Food Handlers in Japan. J. Clin. Microbiol.
45: 3996-4005
[Abstract]
[Full Text]
-
Farkas, T., Deng, X., Ruiz-Palacios, G., Morrow, A., Jiang, X.
(2006). Development of an enzyme immunoassay for detection of sapovirus-specific antibodies and its application in a study of seroprevalence in children.. J. Clin. Microbiol.
44: 3674-3679
[Abstract]
[Full Text]
-
Hansman, G. S., Natori, K., Shirato-Horikoshi, H., Ogawa, S., Oka, T., Katayama, K., Tanaka, T., Miyoshi, T., Sakae, K., Kobayashi, S., Shinohara, M., Uchida, K., Sakurai, N., Shinozaki, K., Okada, M., Seto, Y., Kamata, K., Nagata, N., Tanaka, K., Miyamura, T., Takeda, N.
(2006). Genetic and antigenic diversity among noroviruses.. J. Gen. Virol.
87: 909-919
[Abstract]
[Full Text]
-
Moe, C. L., Sair, A., Lindesmith, L., Estes, M. K., Jaykus, L.-A.
(2004). Diagnosis of Norwalk Virus Infection by Indirect Enzyme Immunoassay Detection of Salivary Antibodies to Recombinant Norwalk Virus Antigen. CVI
11: 1028-1034
[Abstract]
[Full Text]
-
Belliot, G., Noel, J. S., Li, J.-F., Seto, Y., Humphrey, C. D., Ando, T., Glass, R. I., Monroe, S. S.
(2001). Characterization of Capsid Genes, Expressed in the Baculovirus System, of Three New Genetically Distinct Strains of ""Norwalk-Like Viruses"". J. Clin. Microbiol.
39: 4288-4295
[Abstract]
[Full Text]
-
Atmar, R. L., Estes, M. K.
(2001). Diagnosis of Noncultivatable Gastroenteritis Viruses, the Human Caliciviruses. Clin. Microbiol. Rev.
14: 15-37
[Abstract]
[Full Text]